Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Lina Kozhaya et al.|Clinical Cancer Research|2012Cited by 225
Data from Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Lina Kozhaya et al.|Unknown|2023Cited by 0
Data from Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Lina Kozhaya et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Lina Kozhaya et al.|Unknown|2023Cited by 0
Supplementary Figure Legend from Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast CancerSylvia Adams, Sandra Demaria, Lina Kozhaya et al.|Unknown|2023Cited by 0